CSIMarket
 
Immunitybio inc   (IBRX)
Other Ticker:  
 
 
Price: $5.1300 $0.22 4.481%
Day's High: $5.23 Week Perf: -0.19 %
Day's Low: $ 4.87 30 Day Perf: 12.01 %
Volume (M): 8,956 52 Wk High: $ 6.93
Volume (M$): $ 45,943 52 Wk Avg: $2.97
Open: $5.03 52 Wk Low: $1.25



 Market Capitalization (Millions $) 2,557
 Shares Outstanding (Millions) 498
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -459
 Cash Flow (TTM) (Millions $) 74
 Capital Exp. (TTM) (Millions $) 42

Immunitybio Inc
Immunitybio Inc. is a biotechnology company that specializes in developing and commercializing immunotherapies for the treatment of various diseases, including cancer and infectious diseases. The company aims to harness the power of the immune system to target and eliminate diseased cells.

Immunitybio's primary focus is on developing novel immunotherapies, such as cancer vaccines and cell therapies, that can activate and enhance the immune response against cancer cells. The company's approach involves utilizing a combination of genetically engineered molecules, peptides, and viral vectors to stimulate the immune system's ability to identify and destroy cancer cells.

In addition to its cancer programs, Immunitybio is also working on developing immunotherapies for infectious diseases, such as HIV/AIDS and the novel coronaviruses. The company's goal is to leverage its expertise in immunology to create innovative treatments that can effectively combat these diseases.

Overall, Immunitybio Inc. aims to revolutionize the field of immunotherapy through its advanced scientific research, strategic collaborations, and commitment to improving patient outcomes.


   Company Address: 3530 John Hopkins Court San Diego 92121 CA
   Company Phone Number: 696-5235   Stock Exchange / Ticker: NASDAQ IBRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

N-803 and Neutralizing Antibodies: A Promising Approach for HIV Viral Control and Cancer Immunotherapy

Published Wed, Mar 6 2024 2:00 PM UTC

N-803 Combined with Neutralizing Antibodies Shows Promise in HIV Viral Control: A Potential Breakthrough in Antiretroviral TherapyIn a recent publication in the online issue of Science, First Release, ImmunityBio, a clinical-stage immunotherapy company, announced positive preclinical data that suggests combination therapy with N-803, an IL-15 superagonist, and broadly neutra...

Product Service News

Promising Breakthrough: N-803 Combined with Natural Killer Cells Demonstrates Potential to Lower HIV Viral Load

Published Tue, Mar 5 2024 2:00 PM UTC

In a groundbreaking pilot study, ImmunityBio has announced significant findings indicating the potential of their immunotherapy drug, N-803, combined with natural killer (NK) cells in reducing the viral load in individuals living with HIV. The encouraging results were published in The Journal of Infectious Diseases, shedding new light on the pursuit of an effective HIV cure....

Product Service News

ImmunityBio Makes Significant Progress in Advancing Cancer Vaccine Trial for Lynch Syndrome participants

Published Wed, Feb 21 2024 2:00 PM UTC

In an exciting development for the field of cancer immunotherapy, ImmunityBio (NASDAQ: IBRX) has announced the completion of enrollment and initial follow-up for the safety portions of a clinical trial focusing on participants with Lynch syndrome. The trial aims to evaluate the efficacy of ImmunityBio's investigational cancer vaccine, a tri-valent combination of antigens del...

Product Service News

Major Boost for Bladder Cancer Treatment: ImmunityBio Trial Shows Improved Physical Function in Majority of Patients

Published Mon, Feb 5 2024 2:00 PM UTC

In a significant development in the oncology world, ImmunityBio, Inc. - a clinical-stage immunotherapy company, disclosed that the quality-of-life study conducted in BCG-unresponsive bladder cancer trail has illustrated tangible improvement in the physical function of cancer patients. The ground-breaking study demonstrates a favorable risk-benefit ratio for N-803 Plus BCG, f...

Financing Agreement

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million: Fueling Progress in Revolutionizing Immunotherapy

Published Tue, Jan 2 2024 11:00 AM UTC

ImmunityBio Secures $320 Million Investment from Oberland Capital, Boosting Commercialization Efforts
CULVER CITY, Calif. - ImmunityBio, a leading clinical-stage immunotherapy company, announced a game-changing development in its financial strategy with an up to $320 million royalty financing and equity investment from Oberland Capital. The transaction, with $210 million...






 

Immunitybio Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com